Oligonucleotide Therapeutics Society Annual Meeting 2026

What analytical approaches are available for oligonucleotide therapeutics?

BioAgilytix selects analytical platforms based on the specific characteristics of each therapeutic. Depending on program needs, our scientists leverage hybridization ligand binding assays, LC-MS, qPCR, ddPCR, and complementary technologies to generate reliable, fit-for-purpose data.

Can BioAgilytix support both ligand binding assays and LC-MS?

Yes. Our integrated scientific teams develop complementary analytical strategies that leverage both ligand binding assays and LC-MS when appropriate, helping sponsors address complex bioanalytical questions across development.

How are metabolites evaluated for oligonucleotide therapeutics?

LC-MS provides highly sensitive characterization of oligonucleotide metabolites while supporting quantitative bioanalysis throughout development. Our scientists work with sponsors to determine the most appropriate analytical strategy based on therapeutic design and study objectives.

When should biomarker strategies be incorporated?

Biomarker planning is most effective when considered early in development. Early integration can support pharmacodynamic assessments, patient safety, efficacy evaluation, and overall development strategy.

Can BioAgilytix support global clinical studies?

Yes. Our harmonized laboratory network supports bioanalytical programs across North America, Europe, and Australia, helping sponsors maintain consistent analytical methods and data quality throughout global clinical development.

What therapeutic modalities does BioAgilytix support?

Beyond oligonucleotides, BioAgilytix supports biologics, monoclonal antibodies, multidomain therapeutics, ADCs, proteins, peptides, gene therapies, cell therapies, vaccines, and other emerging therapeutic modalities.